Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 20Carcinoma, Non-Small-Cell Lung 20Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Lung Neoplasms 14Mouth Neoplasms 10Laryngeal Neoplasms 10Carcinoma 10Urinary Bladder Neoplasms 8Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 6Mesothelioma, Malignant 6Medulloblastoma 6Gallbladder Neoplasms 6Neuroblastoma 5Ganglioneuroblastoma 5Fallopian Tube Neoplasms 5Lymphoid Interstitial Pneumonia 4Vulvar Neoplasms 3Urethral Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Carcinoma, Transitional Cell 3Brenner Tumor 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

National Cancer Institute (NCI)

Phase 2 Completed
344 enrolled 11 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡